Based on their critical role in cell signaling, PKC agonists are being evaluated preclinically and clinically for treatment of neurologic disorders such as Alzheimer’s disease, various cancers, and HIV infection [11–13,16,17,19]. The gene discussed is PRRT2; the disease is cancer.